Silvio Inderbitzin

Aurealis Oy operates as a biopharmaceutical company which develops treatment method that improves life for chronic inflammation and cancer sufferers. It develops a proprietary technology, which utilizes genetically modulated probiotics that deliver a variety of therapeutic proteins to diseased tissue, thus modulating local immune system and enabling healing. The company was founded by Dirk Weber and Thomas Wirth in 2010 and is headquartered in Kuopio, Finland.

Cellestia Biotech AG manufactures anti-cancer drugs. Its pipeline product includes CB-103, a novel oral pan-NOTCH inhibitor for the treatment of NOTCH dependent leukemia, lymphoma, and solid tumors. The firm holds a worldwide exclusive license on the intellectual property rights for the development and commercialization of CB-103 and related series of close analogues. The company was founded by Freddy Radtke, Michael Bauer, Richard Peck, Dirk Weber and Rajwinder Lehal in 2014 and is headquartered in Basel, Switzerland.

Mavena International AG develops, manufactures, and markets medical care products for the treatment of chronic skin conditions. The company is headquartered in Huneberg, Switzerland.

Strekin AG is a Swiss pharmaceutical company that develops pharmaceuticals, therapeutics, and vaccines. The private company was founded in 2014 and is based in Basel, Switzerland.

Part of Aurealis Oy, Aurealis Pharma AG is a Swiss company that provides scientific research and development services. The company is based in Basel, Switzerland. The company was founded by Juha Matti Yrjänheikki.

Artidis AG develops nano mechanical biomarkers for rapid cancer diagnostics. The private company is based in Basel, Switzerland. The Swiss company was founded by Marija Plodinec, Marko Loparic, Philipp Oertle, Tobias Appenzeller. Marija Plodinec has been the CEO since incorporation.

Part of Kinarus Therapeutics Holding AG, Kinarus AG is a Swiss clinical stage pharmaceutical company that focuses on novel treatments to patients suffering from viral, respiratory and ophthalmic diseases. The company is based in Basel, Switzerland. The company was founded in 2017 by Alexander Bausch, Roger Meier. Alexander Bausch has been the CEO since 2017. Kinarus was acquired by Perfect Holding SA on June 03, 2022.

Curatis Holding AG is a clinical-stage biopharmaceutical company. It engages in the business of discovering and developing novel therapeutics for the treatment of viral, respiratory, and ophthalmic diseases. The company was founded on April 8, 1997 and is headquartered in Basel, Switzerland.